These results showed that lipotecan-based CRT indeed increased H2k1 and Tap1 expression for cancer immunogenicity (Figure 5A,C) and had no influence on B2m expression (Figure 5B), which indicated that lipotecan remodulated cancer immunogenicity within the TME. The gene discussed is TAP1; the disease is cancer.